Background: Systemic inflammation may adversely affect the lipid profile in AS and PsA patients (pts)1. Treatment with some TNF and JAK inhibitors have reported increased total cholesterol (TC) and triglycerides (TG) despite reduction in inflammation2-3. Secukinumab (SEC), a fully human monoclonal antibody that directly inhibits IL-17A, has demonstrated a sustained efficacy and consistent safety profile in pts with AS and PsA4

Objectives: To evaluate the long-term effect of SEC on key lipid parameters in AS and PsA pts from pooled phase 3 clinical trials, through 208 weeks (wks)

Methods: This post hoc analysis included pooled data from MEASURE 1-4 (SEC 150 mg) in AS (N = 892) and FUTURE 2-5 studies (SEC 150/300 mg) in PsA (N = 2049), from pts treated with SEC or placebo (PBO). Serum TC, TG, LDL- and HDL-cholesterol and TC/HDL-C levels were assessed at baseline (BL), Wks 16, 104 and 208 in overall population and in sub-groups by prior anti-TNF therapy, concomitant methotrexate (MTX) and BL statin usage. Shift of common terminology criteria for adverse events (CTCAE) grade from BL through Wk 208 were also analysed

Results: BL characteristics were comparable across SEC and PBO groups. Lipid levels were stable in SEC treated AS and PsA pts through Wk 208 (Table) with mean change (mmol/L) from BL in AS: TC = ±0.1, TG = 0.1-0.2, LDL-C = ±0.1, HDL-C = ±0.04 and TC/HDL-C = ±0.2 and PsA: TC = ±0.2, TG = 0.001-0.2, LDL-C = ±0.2, HDL-C = ±0.06 and TC/HDL-C = ±0.2. Stable lipid values were also seen across key sub-groups by prior anti-TNF therapy, concomitant MTX and BL statin usage, which remained stable through Wk 208. No Change in CTCAE lipid grades was observed in >90% of SEC-treated pts through Wk 208

Conclusion: SEC did not adversely affect the lipid profile and TC/HDL-C ratio in pts with AS and PsA, over 4 years. The lipid profile remained stable with SEC treatment and was sustained irrespective of prior anti-TNF status, concomitant MTX and BL statin usage